Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Eleni Efstathiou, MD, Houston Methodist Cancer Center

Videos

Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Scott Tagawa, MD, Weill Cornell Medicine

Videos

Anti-PSMA Salvage Radio-Immunotherapy for Castration-Resistant Prostate Cancer

02/16/2023

Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, presents...

02/16/2023

Oncology

Srikala Sridhar, MD, Princess Margaret Cancer Center

Videos

Impact of COVID-19 on Treatment of Patients With Metastatic Hormone Sensitive Prostate Cancer

12/20/2022

Srikala Sridhar, MD, shares insights from a study investigating how metastatic hormone sensitive prostate cancer care has changed during the COVID-19 pandemic.

Srikala Sridhar, MD, shares...

12/20/2022

Oncology

Quiz

Quiz: Olaparib Added to Abiraterone for Metastatic Castration-Resistant Prostate Cancer

11/30/2022

True or False: In the phase 3 PROpel study, the addition of olaparib to abiraterone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer, compared to abiraterone alone.

True or False: In the phase 3...

11/30/2022

Oncology

Ana Aparicio, MD, MD Anderson Cancer Center

Videos

Treatment Approaches for Aggressive Variants of Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Ana Aparicio, MD, discusses aggressive variants of metastatic castration-resistant prostate cancer, with a focus on treatment approaches for patients with androgen-indifferent disease.

Ana Aparicio, MD, discusses...

11/10/2022

Oncology

Stephane Oudard, MD, Hôpital Européen Georges-Pompidou

Videos

Adapted Cabazitaxel Schedule Reduces Neutropenic Complications in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

11/10/2022

Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...

Stéphane Oudard, MD, reports...

11/10/2022

Oncology

Fred Saad, MD, University of Montréal Hospital Center

Videos

Olaparib Prolongs Radiographic PFS vs Placebo in Metastatic Castration-Resistant Prostate Cancer Across Subgroups

10/18/2022

Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, discusses...

10/18/2022

Oncology

Christian Rothermundt, MD, Kantonsspital St Gallen

Videos

Enzalutamide Plus Metformin Conveyed No Benefit for Disease Control Rate of Patients With Metastatic Castration-Resistant Prostate Cancer

10/12/2022

Dr Christian Rothermundt reviews the results of a phase 2 trial presented at the 2022 ESMO Congress, which demonstrated that adding metformin to enzalutamide conveyed no benefit for disease control rate of patients with metastatic...

Dr Christian Rothermundt reviews...

10/12/2022

Oncology

Evan Yu, MD, Fred Hutchinson Cancer Center

Videos

Pembrolizumab Plus Olaparib Conveyed No Survival Benefit in Metastatic Castration-Resistant Prostate Cancer

09/29/2022

Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...

Evan Yu, MD, reviews the results...

09/29/2022

Oncology

Joseph Renzulli, MD, Yale School of Medicine

Videos

Enzalutamide Reduces Risk of Disease Progression in Low- and Intermediate-Risk Prostate Cancer

09/12/2022

Joseph Renzulli, MD, discusses findings from the phase 2 ENACT trial, evaluating enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized prostate cancer.

Joseph Renzulli, MD, discusses...

09/12/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology